Preferential inhibition of by MCI-154, a putative cardiotonic Ca2+ sensitizer, in guinea pig atrial cells

Cardiovascular Research

Volumn 38, Issue 3, 1998, Pages 685-694

  Eto, Koji ^a,c   Hashimoto, Keitaro ^a   Nakaya, Haruaki ^b  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Action potential duration; Ca2+ sensitizer; MCI 154; Negative chronotropism; The delayed rectifier K+ current

Indexed keywords

4,5 DIHYDRO 6 [4 (4 PYRIDYLAMINO)PHENYL] 3(2H) PYRIDAZINONE; AMRINONE; ENOXIMONE; MILRINONE; PHOSPHODIESTERASE INHIBITOR; CARDIOTONIC AGENT; POTASSIUM CHANNEL; PYRIDAZINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CALCIUM CONDUCTANCE; CALCIUM CURRENT; CHRONOTROPISM; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HEART AUTOMATICITY; HEART MUSCLE POTENTIAL; INOTROPISM; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; SINUS NODE CONDUCTION VELOCITY; SINUS NODE MEMBRANE POTENTIAL; ACTION POTENTIAL; ANIMAL; CELL CULTURE; CHEMICAL PHENOMENA; DOSE RESPONSE; GUINEA PIG; HEART ATRIUM; MICROELECTRODE; PATCH CLAMP; SINUS NODE;

ACTION POTENTIALS; ANIMALS; CARDIOTONIC AGENTS; CELLS, CULTURED; DEPRESSION, CHEMICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; HEART ATRIA; MICROELECTRODES; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; PYRIDAZINES; SINOATRIAL NODE;

EID: 0032081282     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00048-0     Document Type: Article

References (37)

1. [1] Simonton CA, Chatterjee K, Cody RJ, et al. Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation. J Am Coll Cardiol 1985;6:453-459.
2. [2] Massie B, Bourassa M, DiBianco R, et al. Long-term oral amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation 1985;71:963-971.
3. [3] DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. New Engl J Med 1989;320:677-683.
4. [4] Utrtsky BF, Jessup M, Konstam MA, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation 1990;82:774-780.
5. [5] Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. New Engl J Med 1991;325:1468-1475.
6. [6] Malecot CO, Bers DM, Katzung BG. Biphasic concentrations induced by milrinone at low temperature in ferret ventricular muscle: role of the sarcoplasmic reticulum and transmembrane calcium influx. Circ Res 1986;59:151-162.
7. [7] Brunkhorst D, Leyden H, Meyer W, Nigubur R, Scmidtschumacher C, Scholz H. Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea pig heart. Naunyn-Schmiedeberg's Arch Pharmacol 1989;339:575-603.
8. [8] Hála O, Marton A, Varró A, Papp JGy. Effects of levosimendan and milrinone on slow response and delayed after depolarization. J Mol Cell Cardiol 1994;26:LXXXIII.
9. 2+ sensitivity of the contractile system by MCI-154, a novel cardiotonic agent, in chemically skinned fibers from the guinea pig papillary muscles. J Pharmacol Exp Ther 1987;243:633-638.
10. [10] Kitada Y, Narimatsu A, Suzuki R, Endoh M, Taira N. Does the positive inotropic action of a novel cardiotonic agent, MCI-154, involve mechanisms other than cyclic AMP?. J Pharmacol Exp Ther 1987;243:639-645.
11. [11] Lues I, Beier N, Jonas R, Klockow M, Haesler G. The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers. J Cardiovasc Pharmacol 1993;21:883-892.
12. [12] Végh Á, Papp JGy, Udvary É, Kaszala K. Hemodynamic effects of calcium-sensitizing agents. J Cardiovasc Pharmacol 1995;26:20-31. (Suppl I).
13. 2+ sensitizer, on ventricular arrhythmias and membrane ionic currents. Eur J Pharmacol 1996;298:247-256.
14. [14] Allert JA, Adams HR. Inotropic and chonotropic profile of MCI-154: comparison with isoprenaline and imazodan in guinea pig cardiac preparations. J Cardiovasc Pharmacol 1990;16:59-67.
15. [15] Abe Y, Kitada Y, Narimatsu A. Beneficial effects of MCI-154, a cardiotonic agent, on ischemic contractile failure and myocardial acidosis of dog hearts: comparison with dobutamine, milrinone and pimobendan. J Pharmacol Exp Ther 1992;261:1087-1095.
16. [16] Mori K, Hara Y, Saito T, Masuda Y, Nakaya H. Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells: different molecular mechanisms. Circulation 1995;91:2834-2843.
17. [17] Ono K, Tsujimoto G, Sakamoto A, et al. Endothelin-A receptor mediates cardiac inhibition by regulating calcium and potassium currents. Nature 1994;370:301-304.
18. + channels. J Pharmacol Exp Ther 1985;234:134-140.
19. [19] Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflügers Arch 1981;391:85-100.
20. + current: Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990;96:194-214.
21. + current is composed of two currents in guinea pig atrial cells. Am J Physiol 1991;260:H393-399.
22. [22] Katz AM. Physiology of the heart. 2nd edn. New York: Raven Press, 1992.
23. [23] Varró A, Papp JGy. Classification of positive inotropic actions based on electrophysiologic characteristics: where should calcium sensitizers be placed?. J Cardiovasc Pharmacol 1995;26:S32-S44. (Suppl 1).
24. [24] Ravens U, Flüß MO, Li Q, et al. Stereoselectivity of actions of the calcium sensitizer (+)-EMD 60263 and its enantiomer (-)-EMD 60264. Naunyn-Schmiedeberg's Arch Pharmacol 1997;355:733-742.
25. [25] Satoh H, Hashimoto K. Effect of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazyl]-2(1H)-quinolinone (OPC-8212) on the membrane currents of rabbit sino-atrial node cells. Arzneim-Forsch 1984;34:376-380.
26. [26] Hosokawa T, Mori T, Fujiki H, et al. Cardiovascular actions of OPC-18790: a novel positive inotropic agent with little chronotropic action. Heart Vessels 1992;7:66-75.
27. [27] Iijima T, Taira N. Membrane current changes responsible for the positive inotropic effect of OPC-8212, a new positive inotropic agent, in single ventricular cells of the guinea pig heart. J Pharmacol Exp Ther 1987;240:657-662.
28. [28] Lathrop DA, Nánási PP, Schwartz A, Varró A. Ionic basis for OPC-8212 induced increase in action potential duration in isolated rabbit, guinea pig and human ventricular myocytes. Eur J Pharmacol 1993;240:127-137.
29. [29] Yang T, Snyder DJ, Roden DM. Inhibition of cardiac potassium currents by the vesnarinone analog OPC-18790: Comparison with quinidine and dofetilide. J Pharmacol Exp Ther 1997;280:1170-1175.
30. [30] Verheijck EE, van Ginneken ACG, Bourier J, Bouman LN. Effects of delayed rectifier current blockade by E-4031 on impulse generation in single sinoatrial node myocytes of the rabbit. Circ Res 1995;76:607-615.
31. 2+-regulated interactions between troponin subunits from bovine heart. J Pharmacol Exp Ther 1994;270:831-840.
32. 2+ sensitivity of reconstituted thin filament: a study using a novel in vitro motility assay technique. Circ Res 1995;76:626-633.
33. [33] Virág L, Hála O, Marton A, Varró A, Papp JGy. Cardiac electrophysiological effects of levosimendan, a new calcium sensitizer. Gen Pharmacol 1996;27:551-556.
34. [34] Lathrop DA, Nánási PP, Varró A, Schwartz A. Comparison of the electromechanical effects of vesnarinone and amrinone in isolated dog Purkinje strands and ventricular trabeculae. J Cardiovasc Pharmacol Ther 1996;1:133-140.
35. [35] Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. New Engl J Med 1993;329:149-155.
36. [36] Reddy S, Benatar P, Gheorghiade M. Update on digoxin and other oral positive inotropic agents for chronic heart failure. Curr Opin Cardiol 1997;12:233-241.
37. [37] van Zwieten PA. Current and newer approaches in the drug treatment of congestive heart failure. Cardiovasc Drug Ther 1997;10:693-702.